Venus Medtech (Hangzhou) Inc. (HKG:2500)

Market Cap	446.66M -79.3%
Revenue (ttm)	341.39M -34.8%
Net Income	-453.68M
EPS	-1.04
Shares Out	437.90M
PE Ratio	n/a
Forward PE	97.18
Dividend	n/a
Ex-Dividend Date	n/a

Volume	480,500
Open	1.040
Previous Close	1.040
Day's Range	1.005 - 1.040
52-Week Range	0.940 - 4.830
Beta	1.16
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 31, 2026

About Venus Medtech (Hangzhou)

Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2009
• Employees: 560
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2500

Financial Performance

In 2025, Venus Medtech (Hangzhou)'s revenue was 306.79 million, a decrease of -34.84% compared to the previous year's 470.83 million. Losses were -407.69 million, -42.92% less than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 21, 2026

Data Sources Report a data error